(CercleFinance.com) – Bristol Myers Squibb announces the success of its takeover bid (OPA) for RayzeBio shares, for a purchase price of $62.50 per share, or approximately $4.1 billion, Takeover bid which expired last night.
Equiniti Trust Company, the depository for the offering, has informed that as of the expiration date, approximately 53,052,499 shares have been validly tendered, representing approximately 86% of the issued and outstanding common shares of RayzeBio.
The parties expect the transaction to close on February 26, shortly after acceptance of all shares of common stock validly tendered and not validly withdrawn pursuant to the offer.
Copyright © 2024 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends using the buttons below.
